Lonza, the healthcare development and manufacturing organization, has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for $1.2 billion.   The Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the US, the world’s largest pharmaceutical market. It also creates a significant West Coast commercial manufacturing presence close to San Francisco’s pharma and biotech hub, complementing L...